Publications by authors named "Roberto Faggiani"

Claim this Profile
U
Upadacitinib's Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World Study.
Giammarco Mocci, Antonio Tursi, Franco Scaldaferri, Daniele Napolitano, Daniela Pugliese, Roberto Faggiani

J Clin Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: a systematic literature review and meta-analysis.
Marc Ferrante, Laurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, Jean-Frédéric Colombel, Roberto Faggiani

Therap Adv Gastroenterol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hospital Admission, Medical, and Surgical Procedures for Acute Diverticulitis Are More Appropriate when Using a Diagnostic and Therapeutic Assistance Pathway: An Experience from a Referral Center.
Walter Elisei, Pierluigi Marini, Roberto Faggiani, Stefano Manfroni, Gabriele Ricci

Dig Dis· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort Study.
Giammarco Mocci, Antonio Tursi, Franco Scaldaferri, Daniele Napolitano, Daniela Pugliese, Roberto Faggiani

J Clin Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study.
Antonio Tursi, Giammarco Mocci, Franco Scaldaferri, Daniele Napolitano, Rossella Maresca, Roberto Faggiani

Expert Opin Biol Ther· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study.
Antonio Tursi, Giammarco Mocci, Linda Cingolani, Edoardo Savarino, Roberta Pica, Roberto Faggiani

Expert Opin Pharmacother· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Earlier You Find, the Better You Treat: Red Flags for Early Diagnosis of Inflammatory Bowel Disease.
Laura Cantoro, Rita Monterubbianesi, Giuliano Falasco, Caterina Camastra, Paolo Pantanella, Roberto Faggiani

Diagnostics (Basel)· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.
Antonio Tursi, Giammarco Mocci, Leonardo Allegretta, Giovanni Aragona, Maria Antonia Bianco, Roberto Faggiani

Inflamm Bowel Dis· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study.
Giammarco Mocci, Antonio Tursi, Giovanni Maconi, Giovanni Cataletti, Beatrice Mantia, Roberto Faggiani

Expert Opin Biol Ther· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy.
Antonio Tursi, Giammarco Mocci, Antonio Cuomo, Antonio Ferronato, Walter Elisei, Roberto Faggiani

J Gastrointestin Liver Dis· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy.
Antonio Tursi, Giammarco Mocci, Leonardo Allegretta, Giovanni Aragona, Maria Antonia Bianco, Roberto FaggianI

Expert Opin Biol Ther· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of ustekinumab in patients with refractory Crohn's disease: a multicentre real-life study in Italy.
Maria Lia Scribano, Annalisa Aratari, Benedetto Neri, Cristina Bezzio, Paola Balestrieri, Roberto Faggiani

Therap Adv Gastroenterol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term, Real-life, Observational Study in Treating Outpatient Ulcerative Colitis with Golimumab.
Antonio Tursi, Giammarco Mocci, Walter Elisei, Leonardo Allegretta, Raffaele Colucci, Roberto Faggiani

J Gastrointestin Liver Dis· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A prospective study on quality in endoscopic retrograde cholangiopancreatography (ERCP): trend in Italy from the REQUEST study.
Giulio Donato, Pietro Occhipinti, Loredana Correale, Marco Spadaccini, Alessandro Repici, Roberto Faggiani

Endosc Int Open· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients.
Antonio Tursi, Giammarco Mocci, Roberto Lorenzetti, Leonardo Allegretta, Giovanni Brandimarte, Roberto Faggiani

Eur J Gastroenterol Hepatol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centers.
Antonio Tursi, Giammarco Mocci, Roberto Faggiani, Leonardo Allegretta, Nicola Della Valle

Eur J Intern Med· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centers.
Antonio Tursi, Giammarco Mocci, Roberto Faggiani, Leonardo Allegretta, Nicola Della Valle

Ann Gastroenterol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: A real-life multicenter, observational study in primary inflammatory bowel disease centers.
Antonio Tursi, Walter Elisei, Roberto Faggiani, Leonardo Allegretta, Nicola Della Valle

Medicine (Baltimore)· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and Safety of Golimumab in Treating Outpatient Ulcerative Colitis: A Real-Life Prospective, Multicentre, Observational Study in Primary Inflammatory Bowel Diseases Centers.
Antonio Tursi, Leonardo Allegretta, Nello Buccianti, Nicola Della Valle, Walter Elisei, Roberto Faggiani

J Gastrointestin Liver Dis· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive value of the Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification on the outcome of diverticular disease of the colon: An international study.
Antonio Tursi, Giovanni Brandimarte, Francesco Di Mario, Maria L Annunziata, Mauro Bafutto, Roberto Faggiani

United European Gastroenterol J· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and validation of an endoscopic classification of diverticular disease of the colon: the DICA classification.
Antonio Tursi, Giovanni Brandimarte, Francesco Di Mario, Arnaldo Andreoli, Maria Laura Annunziata, Roberto Faggiani

Dig Dis· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Managing ambulatory ulcerative colitis patients with infliximab: a long term follow-up study in primary gastroenterology centers.
Antonio Tursi, Walter Elisei, Marcello Picchio, Antonio Penna, Piera Giuseppina Lecca, Roberto Faggiani

Eur J Intern Med· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres.
Antonio Tursi, Walter Elisei, Marcello Picchio, Antonio Penna, Piera Giuseppina Lecca, Roberto Faggiani

Eur J Intern Med· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of adalimumab for ambulatory ulcerative colitis patients after failure of infliximab treatment: a first "real-life" experience in primary gastroenterology centers in Italy.
Antonio Tursi, Walter Elisei, Marcello Picchio, Antonio Penna, Giacomo Forti, Roberto Faggiani

Ann Gastroenterol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Granulomatous interstitial nephritis in a patient with Crohn's disease.
Rosaria Polci, Mario Mangeri, Roberto Faggiani, Emanuela Cristi, Teresa Valentina Ranalli

Ren Fail· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis